Pill Politics : Drugs and the FDA /

From aspirin to Viagra to the latest cancer treatment, the Food and Drug Administration acts as a gatekeeper determining what medicines are legally available in the United States. But in fulfilling that regulatory role, Stephen Ceccoli argues, the FDA may inadvertently be promoting new drugs at the...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autor: Ceccoli, Stephen J. (Autor)
Médium: E-kniha
Jazyk:angličtina
Vydáno: Boulder : Lynne Rienner Publishers, [2022]
Témata:
ISBN:9781626374102
On-line přístup: Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

MARC

LEADER 00000nam a22000005i 4500
003 DE-B1597
005 20230526123059.0
006 m|||||o||d||||||||
007 cr || ||||||||
008 220629t20222004cou fo d z eng d
020 |a 9781626374102 
040 |a DE-B1597  |b eng  |c CVT  |e AACR2  |d CVT 
041 0 |a eng 
044 |a cou  |c US-CO 
072 7 |a 615  |2 CVT 
080 |a 615  |2 2011 
080 |a 615:346.54  |2 2011 
100 1 |a Ceccoli, Stephen J.,   |e author.  |4 aut  |4 http://id.loc.gov/vocabulary/relators/aut 
245 1 0 |a Pill Politics :  |b Drugs and the FDA /  |c Stephen J. Ceccoli. 
260 1 |a Boulder :   |b Lynne Rienner Publishers,   |c [2022] 
300 |a 1 online resource (211 p.) 
505 0 0 |t Frontmatter --   |t Contents --   |t Tables and Figures --   |t Acknowledgments --   |t 1. Putting the FDA into Perspective --   |t 2. The Politics of Assessing Drugs --   |t 3. An Evolving Regulatory Balance --   |t 4. The Drug Lag Debate and Demands for Reform --   |t 5. A Grand Compromise and the Shift to a New Era --   |t 6. Whither the FDA? --   |t 7. Protecting and Promoting Public Health in the United States --   |t Appendix: Drug Development and the FDA's Approval Process --   |t List of Abbreviations --   |t Notes --   |t Bibliography --   |t Index --   |t About the Book 
516 |a text file PDF 
520 |a From aspirin to Viagra to the latest cancer treatment, the Food and Drug Administration acts as a gatekeeper determining what medicines are legally available in the United States. But in fulfilling that regulatory role, Stephen Ceccoli argues, the FDA may inadvertently be promoting new drugs at the expense of public health.The FDA's initial mandate to protect health grew out of pharmaceutical-related disasters in the early 1900s. Later criticisms that the agency's approach impeded industry competitiveness and failed to meet public need, however, led to a political compromise on its mission. The new FDA has cut its review time nearly in half and allows direct-to-consumer advertising, off-label promotion of drugs, and the "fast-tracking" of treatments. Ceccoli convincingly shows that this approval process, while redressing valid complaints, is also creating a new complex of problems that must be resolved. 
650 7 |a MEDICAL / Health Policy.  |2 bisacsh 
653 |a farmácia 
653 |a riadenie farmácie 
856 4 0 |u https://erproxy.cvtisr.sk/sfx/access?url=www.degruyter.com/document/isbn/9781626374102/html  |y Vzdialený prístup pre registrovaných používateľov 
910 |b ZE13377 
919 |a 978-1-62637-410-2 
959 |a 56 
992 |a SUD 
999 |c 300496  |d 300496 
974 |b Rita Zubonyaiová